Personalized Medicine Coalition Award for Leadership Awarded Moffitt Cancer Center CEO

Today at the Personalized Medicine: Impacting Healthcare conference, the premier gathering of leaders in the personalized medicine field, the Personalized Medicine Coalition presented its annual award for Leadership in Personalized Medicine to Moffitt Cancer Center President, CEO and Center Director William Dalton, Ph.D., MD.

The award, which recognizes an individual whose contributions in science, business, and/or policy have helped advance the frontiers of personalized medicine, is presented annually at the personalized medicine conference sponsored by Partners HealthCare Center for Personalized Genetic Medicine, Harvard Medical School and Harvard Business School.

Giving this award to Dr. Dalton sends the message that personalized medicine is no longer a promise of the future. It currently has the capacity, especially in cancer, to ensure that the right patients receive the right treatments at the right time.  Under Dr. Dalton’s leadership, Moffitt is paving the way towards a new era of customizing treatments based upon individual characteristics.

Dr. Dalton is also receiving the award in recognition of his leadership in advancing public policies designed to support personalized medicine innovation and clinical application and for Moffitt’s pioneering work to implement personalized medicine concepts both to improve patient outcomes and lower costs.     

He is a leading advocate for health policies that support personalized medicine for the benefit of patients and currently serves as the President-Elect of the Association of American Cancer Institutes (AACI) and is Chair of the Science Policy & Legislative Affairs Committee of the American Association for Cancer Research. 

Dr. Dalton’s work is on the leading edge of personalized cancer care and patient-centered outcomes research. Moffitt’s Total Cancer Care^TM is an approach to enhancing access to evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care^TM is one of the largest cancer tumor bio-repositories and data warehouses in the United States dedicated for use in development of personalized medicine. 

As the recipient of the PMC award, Dr. Dalton joins a group of innovators well recognized for their leadership in personalized medicine. Previous recipients of the award include Dr. Janet Woodcock, Director of the Food and Drug Administration’s Center for Drug Evaluation and Research, Dr. Elizabeth G. Nabel, former Director of the National Heart, Lung and Blood Institute at the National Institutes of Health, Michael Leavitt, former Health and Human Services Secretary, Dr. Ralph Snyderman, Chancellor Emeritus of Duke University and founder of Proventys, Inc., and, most recently, Brook Byers of Kleiner Perkins Caufield & Byers.